Shanghai Haohai Biological Technology Co., Ltd. Class H (HK:6826) has released an update.
Shanghai Haohai Biological Technology Co., Ltd. has reported a solid growth in their interim financial results for the first half of 2024, with a revenue increase of 7% and a 14.64% rise in profits compared to the same period in 2023. The company’s commitment to innovation is evident in the increased R&D spending, which is up by nearly 24%. Additionally, shareholders have a reason to celebrate as the Board proposes a noteworthy interim dividend of RMB0.40 per share.
For further insights into HK:6826 stock, check out TipRanks’ Stock Analysis page.
